Human PilotPubMed ID: 11497032·2001

Cancer immunotherapy: thymosin alpha-1 as melanoma vaccine adjuvant

Schoof DD, Beatty GR, Peoples GE, et al.

Cancer Immunology, Immunotherapy, 2001 · n = 28

Key finding

Thymosin alpha-1 + vaccine induced gp100-specific CD8+ responses (IFN-γ spot-forming cells 312 ± 87/10^6 PBMC) in 18/28 patients.

Summary

Pilot study of thymosin alpha-1 with gp100 melanoma peptide vaccine in advanced melanoma patients, measuring immune responses and tumor burden.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study